Imaging of 186Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis.
Imaging of 186Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis.
复制标题
186Re-脂质体治疗腹膜癌病卵巢癌异种移植模型的成像。
DOI：
10.1080/10611860802230372
复制
发表时间：
2008
影响因子：
4.5
通讯作者：
Phillips,WilliamT
中科院分区：
文献类型：
--
作者：
Zavaleta,CristinaL;Goins,BethA;Bao,Ande;McManus,LindaM;McMahan,CAlex;Phillips,WilliamT
本研究确定了包封在含有专利蓝染料的生物素脂质体中的186 Re（186 Re）的生物分布，在OVCAR-3卵巢癌异种移植模型中腹膜内（IP）注射抗生物素蛋白，并使用氟-18-氟脱氧葡萄糖（18 F-FDG）microPET成像评估了该疗法的肿瘤反应。在IP注射抗生物素蛋白（5 mg）前30 min，治疗组大鼠（n= 8）接受IP注射186 Re-蓝-生物素-脂质体（1000 MBq/kg），而对照组大鼠（n= 4）接受假IP注射生理盐水。闪烁照相显示186 Re-蓝-生物素脂质体/亲和素在腹腔内滞留，5天后仍有18%的活性保留。治疗后1 ~ 4周，治疗组18F-FDG标准摄取值下降30%，对照组上升44%。腹水中的细胞总数在对照组中显著高于治疗组。对照组大鼠网膜脂肪中有大量的肿瘤细胞相比，治疗组大鼠。结果显示186 Re-蓝-生物素-脂质体/亲和素系统治疗晚期卵巢癌腹膜转移的潜力。
This study determined the biodistribution of rhenium-186 (186Re) encapsulated in biotin-liposomes containing patent blue dye, injected intraperitoneally (IP) with avidin in an OVCAR-3 ovarian cancer xenograft model and evaluated tumor response of this therapy with fluorine-18-fluorodeoxyglucose (18F-FDG) microPET imaging. Treated rats (n= 8) received an IP injection of186Re-blue-biotin-liposomes (1000 MBq/kg) 30 min before an IP injection of avidin (5 mg), whereas control rats (n= 4) received a sham IP injection of saline. Scintigraphic images showed that186Re-blue-biotin liposomes/avidin were retained in the peritoneal cavity with 18% of the original activity remaining after 5 days. From 1 to 4 weeks post-treatment, peritoneal18F-FDG standard uptake values decreased 30% in treatment group, yet increased 44% in control group. Total number of cells in ascites was significantly higher in control versus treatment group. Omental fat in control rats had numerous tumor cells compared with treated rats. Results show the potential for186Re-blue-biotin-liposome/avidin system in treating advanced ovarian cancer involving peritoneal carcinomatosis.